Pipeline

August 5, 2019

Company	Drug/Device	Medical Condition	Status
Miracor Medical SA	PiCSO therapy	heart attack	Phase 1 trial initiated enrolling 114 subjects with anterior STEMI, TIMI 0 & 1 Flow, at nine clinical sites in Western Europe
Reflow Medical, Inc.	Temporary Spur Stent System	peripheral artery disease (PAD), occlusive disease affecting below-the-knee (BTK) arteries	Phase 1 trial initiated
I-Mab Biopharma Tracon Pharmaceuticals, Inc.	TJD5 (TJ004309)	advanced solid tumors	Phase 1 trial initiated
AC Immune SA	ACI-35.030	Alzheimer’s disease (AD)	Phase 1b/2a trial initiated
Proteostasis Therapeutics, Inc.	cystic fibrosis transmembrane conductance regulator (CFTR) modulator combinations doublet (PTI-808 and PTI-801) and triplet (PTI-808, PTI-801 and PTI-428)	cystic fibrosis (CF)	Phase 2 trial initiated enrolling 30 F508del homozygous and 30 F508del heterozygous subjects
Arena Pharmaceuticals	olorinab	gastrointestinal (GI) disorders	Phase 2 trial initiated enrolling 240 subjects experiencing abdominal pain associated with IBS, including IBS with constipation (IBS-C) or IBS with diarrhea (IBS-D) in sites across the U.S.
Relmada Therapeutics, Inc.	REL-1017 (dextromethadone)	treatment-resistant depression	Phase 2 trial initiated enrolling 62 subjects
BELLUS Health Inc.	BLU-5937	chronic cough	Phase 2 trial initiated enrolling 65 subjects with refractory chronic cough at 12 sites in the U.S. and U.K.
Auris Medical Holding Ltd.	AM-125	acute vertigo	Phase 2 trial initiated enrolling 138 subjects who suffer from acute vertigo following surgical removal of a vestibular schwannoma in six European countries and Canada
Resolve Therapeutics	RSLV-132	Systemic Lupus Erythematosus	Phase 2a trial initiated enrolling 64 subjects at 20 sites across the U.S.
Abivax	ABX464-301	moderate to severe active rheumatoid arthritis (RA)	Phase 2a trial initiated enrolling 60 subjects in France, Poland, Czech Republic and Hungary
Modra Pharmaceuticals B.V.	ModraDoc006/r	metastatic Castration-Resistant Prostate Cancer (mCRPC)	Phase 2b trial initiated enrolling 100 subjects with mCRPC eligible for first line systemic chemotherapy at 40 sites in the U.S. and Europe
Biohaven Pharmaceutical Holding Company Ltd.	verdiperstat	Multiple System Atrophy (MSA)	Phase 3 trial initiated enrolling 250 subjects at 50 sites in the U.S. and Europe
AZTherapies, Inc.	ALZT-OP1	early Alzheimer’s disease	Phase 3 trial initiated enrolling 620 subjects with early stage Alzheimer’s disease, ages 55-79
Nektar Therapeutics Bristol-Myers Squibb	bempegaldesleukin (NKTR-214) in combination with Opdivo (nivolumab)	subjects with previously untreated unresectable or metastatic melanoma	Breakthrough Therapy designation granted by the FDA
Endotronix, Inc.	Cordella Pulmonary Artery (PA) Pressure Sensor System	chronic heart failure	IDE approval granted by the FDA
Intersect ENT	PROPEL mini steroid Straight Delivery System (SDS)	frontal and ethmoid sinus surgery	Approval granted by the FDA
Retrophin, Inc.	THIOLA EC (tiopronin) 100 mg and 300 mg tablets	cystinuria	Approval granted by the FDA
Merck	KEYTRUDA (pembrolizumab)	subjects with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (Combined Positive Score [CPS] ≥10) with disease progression after one or more prior lines of systemic therapy	Approval granted by the FDA
Bayer	Nubeqa (darolutamide)	non-metastatic castration-resistant prostate cancer (nmCRPC)	Approval granted by the FDA